Details of Disease

General Information of Disease (ID: DIS3X247)

Disease Name Type-2 diabetes
Disease Class 5A11: Type 2 diabetes mellitus
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DIS3X247: Type-2 diabetes
ICD Code
ICD-11
ICD-11: 5A11
Disease Identifiers
MONDO ID
MONDO_0005148
MESH ID
D003924
UMLS CUI
C0011860
OMIM ID
125853
MedGen ID
41523
HPO ID
HP:0005978
SNOMED CT ID
44054006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 31 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Albiglutide DM1JEGF Approved NA [1]
Alogliptin DM8WI3R Approved Small molecular drug [2]
Anagliptin DMJXIC9 Approved Small molecular drug [3]
Bexagliflozin DMK56G0 Approved NA [4]
Canagliflozin DMFRM1I Approved Small molecular drug [5]
Dapagliflozin DM28UJG Approved Small molecular drug [6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Approved Small molecular drug [7]
Dulaglutide DMYXBV3 Approved NA [8]
Exenatide DMYHBKN Approved Small molecular drug [9]
Insulin-glargine DMR4HIW Approved Small molecular drug [4]
Linagliptin DMWFJTR Approved Small molecular drug [10]
Liraglutide DM3FXPS Approved Small molecular drug [11]
Lixisenatide DM0QJDC Approved Small molecular drug [12]
Lobeglitazone DMHY3IP Approved Small molecular drug [13]
Meglitinides DM1OFHN Approved Small molecular drug [14]
Metformin DM89QE1 Approved Small molecular drug [3]
Metformin arginine-hemisuccinimide DMTPAM3 Approved NA [15]
Oralgen DM00L5T Approved NA [3]
Panobinostat DM58WKG Approved Small molecular drug [16]
PEGylated IFN beta 1-a DMRH0D5 Approved NA [17]
PF-04971729 DM79VXT Approved Small molecular drug [18]
Pioglitazone DMKJ485 Approved Small molecular drug [19]
Roflumilast DMPGHY8 Approved Small molecular drug [20]
Rosiglitazone XR DMT45MU Approved Small molecular drug [21]
Ryzodeq DMOFP18 Approved NA [22]
Saxagliptin DMGXENV Approved Small molecular drug [23]
Semaglutide DMAGFOD Approved Small molecular drug [18]
Sitagliptin DMGDKXN Approved Small molecular drug [24]
Sotagliflozin DMMLXA9 Approved Small molecular drug [4]
Tofogliflozin DMXFZZB Approved Small molecular drug [25]
Vildagliptin DMYN59P Approved Small molecular drug [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 Drug(s)
This Disease is Treated as An Indication in 201 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
TS-071 DM7F3ZM NDA filed Small molecular drug [27]
CJC-1134-PC DM17N47 Phase 3 NA [28]
CS-038 DM67P0F Phase 3 Small molecular drug [29]
Dutogliptin DMM5VTA Phase 3 NA [30]
Efpeglenatide DMKA2PI Phase 3 NA [31]
Fasiglifam hemihydrate DMTGYSO Phase 3 Small molecular drug [32]
Gemigliptin DMZKGPV Phase 3 Small molecular drug [4]
GFT-505 DM7ZOAE Phase 3 NA [33]
GMA102 DMQIE7U Phase 3 Antibody [34]
GMA105 DM2XSG0 Phase 3 Antibody [35]
HE3286 DMB9U5E Phase 3 Small molecular drug [36]
IDDBCP161883 DMV3DHQ Phase 3 NA [37]
IDegLira DMILCDV Phase 3 NA [38]
Imiglitazar DM7BCWT Phase 3 Small molecular drug [39]
Insulin glargine biosimilar DMMREO0 Phase 3 NA [4]
Insulin long-acting iv DMOACP2 Phase 3 NA [40]
LAI287 DMHLO5G Phase 3 NA [41]
LC-150444 DM09RKB Phase 3 NA [42]
LY900014 DM49EQB Phase 3 NA [43]
MABp1 DM8D13S Phase 3 NA [4]
MAGE-A3 immunotherapeutic DMI0GZT Phase 3 NA [44]
MK-3102 DM3PSUF Phase 3 Small molecular drug [45]
MK-8835A DM4I164 Phase 3 NA [4]
MK-8835B DM407YH Phase 3 NA [4]
NN9068 DM6PE9A Phase 3 NA [46]
ORV-116E DMAB22X Phase 3 NA [47]
PC-DAC:Insulin DMJBHO0 Phase 3 NA [4]
RG7201 DMJRFYB Phase 3 NA [48]
Rotavirus vaccine DMDME06 Phase 3 NA [49]
SAR342434 DMR0EWV Phase 3 NA [4]
TAK-875 DMIM5AP Phase 3 Small molecular drug [50]
U300 DMN72OM Phase 3 Small molecular drug [51]
XOMA 052 DMOKQV7 Phase 3 Antibody [52]
Denagliptin DMZV3SY Phase 2/3 Small molecular drug [53]
HDV-insulin DM9N0TR Phase 2/3 NA [54]
Metformin glycinate DMFE0P1 Phase 2/3 Small molecular drug [55]
ONO-2506 DMCA2PJ Phase 2/3 Small molecular drug [56]
INCB13739 DMLQ3PO Phase 2a Small molecular drug [57]
AC-201 DMB0TNL Phase 2 NA [4]
AMG 151 DMGOFL3 Phase 2 NA [58]
AZ-40140 DM9LKYP Phase 2 NA [9]
BGP-15 DMYDM68 Phase 2 Small molecular drug [59]
BI-187004 DMAT1PF Phase 2 NA [60]
BIOD-123 DM2VDUE Phase 2 NA [4]
BIOD-531 DMQQW1Y Phase 2 NA [61]
BMS-986036 DMIZKEC Phase 2 NA [4]
BTI-320 DMZA43X Phase 2 NA [4]
CAT 1004 DMQBP7R Phase 2 NA [62]
Dance-501 DMQ7D07 Phase 2 NA [4]
DM-71 DMMSIG7 Phase 2 NA [63]
DS-8500 DMUXIRM Phase 2 NA [4]
EV-077 DM1FCDH Phase 2 NA [64]
FK-614 DMY61TJ Phase 2 Small molecular drug [65]
GK1-399 DMLFSMX Phase 2 NA [4]
GSK-1070806 DMQGPLO Phase 2 Antibody [66]
GSK1292263 DMDMXKQ Phase 2 Small molecular drug [67]
GSK2330672 DM4BTH8 Phase 2 NA [68]
Imeglimin DMMQFG2 Phase 2 Small molecular drug [69]
INT131 DMUCD9F Phase 2 Small molecular drug [70]
IONIS-GCCRRX DMWV2N1 Phase 2 NA [4]
IONIS-GCGR-Rx DMB4GD9 Phase 2 Antisense oligonucleotide [4]
IONIS-PTP1BRX DMGTJUP Phase 2 NA [4]
ISIS 113715 DMUPD4G Phase 2 Antisense drug [71]
ISIS-GCCR DMICMNU Phase 2 Antisense drug [72]
ISIS-GCGR DMHNYWP Phase 2 Antisense drug [72]
ISIS-PTP1Brx DMJGVXT Phase 2 Antisense drug [73]
JNJ-16269110 DMPFG7H Phase 2 Small molecular drug [74]
JNJ-41443532 DMDUO8I Phase 2 Small molecular drug [75]
JNJ-64565111 DMVSUH1 Phase 2 NA [4]
JTT-251 DM1945H Phase 2 NA [76]
JTT-654 DM50M2R Phase 2 NA [77]
JTT-851 DMED5J6 Phase 2 NA [78]
KDT-501 DM8R3GM Phase 2 Small molecular drug [4]
KRP-104 DMQDLVW Phase 2 NA [79]
LGD-6972 DMPL9KG Phase 2 NA [4]
LIK-066 DM32NWD Phase 2 NA [80]
LY-2409021 DMZOIP4 Phase 2 NA [81]
LY-2428757 DMKYMS2 Phase 2 NA [82]
LY-2608204 DM4EF9Y Phase 2 Small molecular drug [83]
LY-362884 DMD09CT Phase 2 NA [9]
Managlinat dialanetil DMBYDNE Phase 2 NA [84]
MB07803 DMHU8SJ Phase 2 Small molecular drug [85]
MBX-2044 DMQMTO1 Phase 2 NA [86]
MEDI0382 DMSV60C Phase 2 NA [87]
MEDI4166 DMNFF3F Phase 2 NA [4]
Melogliptin DMVJ6WS Phase 2 NA [88]
MER-3001 DMIVR9K Phase 2 NA [4]
Mesenchymal precursor cell DMUXDKX Phase 2 NA [89]
Mitoglitazone DMIRPSA Phase 2 Small molecular drug [90]
MK-8245 DMG6KXB Phase 2 Small molecular drug [91]
MK-8521 DMVNAYE Phase 2 NA [92]
MLR-1023 DM4RNOT Phase 2 Small molecular drug [4]
MSDC-0602 DMGUI51 Phase 2 Small molecular drug [93]
N-5984 DMUK6HC Phase 2 Small molecular drug [9]
NCX-4016 DMOX1CU Phase 2 Small molecular drug [94]
Neo-Kidney Augment DMS7N5S Phase 2 NA [95]
NGM 282 DMB8PDM Phase 2 NA [96]
NP-01 DMP1W9Z Phase 2 NA [97]
Ocaperidone DMP6B59 Phase 2 Small molecular drug [98]
OI338GT DMNEHY1 Phase 2 NA [4]
ORMD-0901 DMRIO6D Phase 2 NA [99]
PAZ-320 DMU0812 Phase 2 NA [100]
PB-1023 DMZCI04 Phase 2 NA [101]
PE0139 DMB2ZAZ Phase 2 NA [4]
PEG-FGF-21 DMS32OI Phase 2 NA [102]
PF-00734200 DMNM4CK Phase 2 Small molecular drug [103]
PF-04937319 DMQMF4O Phase 2 NA [104]
PF-05175157 DMLQ3OK Phase 2 NA [105]
PF-06291874 DMN94QM Phase 2 NA [106]
REMD 477 DM13OVF Phase 2 Antibody [107]
Remogli ozin-etabonate DMZFV3E Phase 2 NA [108]
Remogliflozin etabonate DMW4YK1 Phase 2 Small molecular drug [4]
RG-7234 DM5RAB9 Phase 2 NA [109]
RO-4998452 DMZJREM Phase 2 NA [110]
RRV-TV rotavirus vaccine DMA1JE0 Phase 2 NA [111]
S-707106 DM3GRKY Phase 2 NA [112]
SAR-260093 DMBJU2G Phase 2 NA [113]
T2 18C3 DM6WE4D Phase 2 NA [114]
TAK-272 DM81UAZ Phase 2 Small molecular drug [115]
TAK-379 DMEYKRN Phase 2 NA [116]
TF0023 DMF61ML Phase 2 NA [4]
Tradjeta DMNQ7N7 Phase 2 NA [4]
TT-401 DMRQ0SA Phase 2 NA [117]
TTP-054 DMBNU1W Phase 2 NA [118]
TTP273 DMZ6RG2 Phase 2 NA [4]
U-Strip Diabetes DMOU86T Phase 2 NA [4]
Ultra-rapid insulin DMNXT8C Phase 2 NA [4]
UNI-rE-4 DMOMI97 Phase 2 NA [28]
VK0612 DMX7AP6 Phase 2 NA [119]
VVP-808 DM6BKG2 Phase 2 NA [120]
YM-543 DMRZBPI Phase 2 NA [121]
ORE-1001 DM471ZH Phase 1/2 Small molecular drug [122]
Rotavax DMAIC6B Phase 1/2 NA [123]
Sodium taurocholate DM3GO0J Phase 1/2 Small molecular drug [124]
Taurocholic Acid DM2LZ8F Phase 1/2 Small molecular drug [125]
1614235 + 2330672 DMD751X Phase 1 Combination drug (small molecular drug) [126]
A-348441 DM25CBW Phase 1 Small molecular drug [127]
ADV-1002401 DMHIPF5 Phase 1 NA [128]
AMG 876 DM1FJ9C Phase 1 NA [129]
APD-597 DM36FOG Phase 1 Small molecular drug [130]
ARI-2243 DMN4D3A Phase 1 NA [131]
AVE0897 DM56VG2 Phase 1 NA [132]
BFKB8488A DMYUZIT Phase 1 NA [4]
BI-135585 DMLJOAF Phase 1 NA [133]
BI-44847 DM2KVM0 Phase 1 NA [134]
BKR-013 DMFO4N7 Phase 1 NA [4]
BMS-820132 DMCX0H7 Phase 1 NA [135]
BMS-903452 DM7JW0B Phase 1 NA [136]
BTI-410 DM3SPY9 Phase 1 Peptide [137]
CLX-0921 DMJQG25 Phase 1 NA [138]
CNTO-3649 DM8L36X Phase 1 NA [139]
CVX 096 DMO23R0 Phase 1 NA [140]
DA-1229 DM4OTWL Phase 1 Small molecular drug [141]
DS-1150b DM029TQ Phase 1 NA [142]
DSP-8658 DM2PYE0 Phase 1 NA [143]
EGT-0001474 DMDPGCS Phase 1 NA [144]
Englitazone sodium DMKPBVX Phase 1 Small molecular drug [145]
GLWL-01 DMI8K5V Phase 1 NA [4]
GSK1614235 DM7I1AQ Phase 1 NA [146]
HIP-2B DM45MR0 Phase 1 NA [4]
HMS5552 DMRYM03 Phase 1 NA [4]
ISF-402 DMKO7EA Phase 1 NA [147]
ISIS 325568 DMEJ4B7 Phase 1 Antisense drug [148]
ISIS-SGLT2 DMDKAIC Phase 1 Antisense drug [72]
JNJ-54728518 DMBV3P8 Phase 1 NA [4]
JTT-252 DM6WWA6 Phase 1 NA [149]
KQ-791 DMK0BTN Phase 1 NA [4]
KU-5039 DMAMMPA Phase 1 NA [4]
LY-2881835 DM5EXJV Phase 1 Small molecular drug [150]
MK-5823 DMMBNDG Phase 1 NA [151]
MK-8655 DM75PHJ Phase 1 NA [152]
MK-8666 DMCZB9N Phase 1 NA [153]
NGM313 DMYNSRH Phase 1 NA [4]
NM504 DM7X99Z Phase 1 NA [154]
NN-1218 DMDGCHR Phase 1 NA [4]
NN-9926 DM1RBT8 Phase 1 NA [155]
NN1406 DMQ7N0C Phase 1 NA [4]
NN9748 DMJUUR2 Phase 1 NA [4]
NOX-700 DMMYRHV Phase 1 NA [156]
NP-500 DMHARE7 Phase 1 NA [157]
OAP-189 DM86EX8 Phase 1 NA [158]
OG987SC DMZK1GW Phase 1 NA [159]
P11187 DMXZOI0 Phase 1 NA [160]
PF-05190457 DM7B2JC Phase 1 NA [161]
PF-05231023 DMQYBSH Phase 1 Antibody [162]
PF-06293620 DMUGBRV Phase 1 NA [163]
PF-06342674 DMASKX9 Phase 1 NA [4]
PF-4603629 DMKOE84 Phase 1 NA [28]
REGN1193 DMYBELW Phase 1 Antibody [164]
Rotavin DM5T96R Phase 1 NA [165]
SAR351034 DM15PG9 Phase 1 NA [166]
SAR425899 DM53IPE Phase 1 NA [4]
SAR438335 DM7QO05 Phase 1 NA [4]
SAR440067 DMRVM71 Phase 1 NA [4]
SRT2379 DM7DAKX Phase 1 NA [167]
SRT3025 DMRAXFH Phase 1 NA [168]
Teneligliptin DMGJCDR Phase 1 Small molecular drug [169]
V-24343 DMJSX9N Phase 1 NA [170]
VRS-859 DMITY4G Phase 1 NA [171]
XL550 DMY93SW Phase 1 NA [172]
ZYDPLA 1 DMU2D0B Phase 1 NA [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 201 Drug(s)
This Disease is Treated as An Indication in 3 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID25470667-Compound-GO-CoA-Tat DME40TS Patented Small molecular drug [173]
PMID26936077-Compound-13 DMXK6LV Patented Small molecular drug [174]
PMID26936077-Compound-34 DMIZL8D Patented Small molecular drug [174]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 53 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Aleglitazar DMTG18I Discontinued in Phase 3 Small molecular drug [175]
Amibegron DMPS14M Discontinued in Phase 3 Small molecular drug [176]
Adyvia DMZ7WKN Discontinued in Phase 2 Small molecular drug [177]
AJD-101 DM98OG0 Discontinued in Phase 2 NA [178]
AKP-020 DM6IPWN Discontinued in Phase 2 NA [179]
ALS 2-0426 DMEKHX0 Discontinued in Phase 2 NA [180]
AZD6370 DMVZSRG Discontinued in Phase 2 NA [181]
CLX-0901 DMGJGWI Discontinued in Phase 2 NA [182]
CRx-401 DM39N7W Discontinued in Phase 2 NA [183]
DM-83 DMIP3EC Discontinued in Phase 2 NA [184]
EML-336 DMML2PX Discontinued in Phase 2 NA [185]
GSK184072 DMMIR1K Discontinued in Phase 2 Small molecular drug [186]
INCB19602 DMRHZBD Discontinued in Phase 2 NA [187]
Indeglitazar DMS56UD Discontinued in Phase 2 Small molecular drug [188]
KRP-297 DM9VHZC Discontinued in Phase 2 Small molecular drug [189]
LY-2523199 DMGE9OA Discontinued in Phase 2 NA [190]
LY-307161 DMIS7DW Discontinued in Phase 2 NA [191]
NVP-DPP728 DM9HKOM Discontinued in Phase 2 Small molecular drug [192]
PSN357 DMDOFE7 Discontinued in Phase 2 Small molecular drug [193]
R-1438 DM2Q5IS Discontinued in Phase 2 NA [194]
Rafabegron DMI1SXB Discontinued in Phase 2 Small molecular drug [195]
RG7685 DMPQC18 Discontinued in Phase 2 NA [196]
RG7697 DMI1XQ9 Discontinued in Phase 2 NA [197]
RGLP-1 DMKIY7F Discontinued in Phase 2 NA [198]
SB-756050 DMXFQS1 Discontinued in Phase 2 NA [199]
TA-6666 DMB3W20 Discontinued in Phase 2 NA [200]
FGF-21 DMB35UN Discontinued in Phase 1/2 NA [201]
ABT-279 DMWVFDH Discontinued in Phase 1 Small molecular drug [202]
APD668 DMN8R2U Discontinued in Phase 1 Small molecular drug [203]
AZD-6714 DMHV3IW Discontinued in Phase 1 NA [204]
BAY-27-9955 DMGDSCK Discontinued in Phase 1 Small molecular drug [205]
GSK-1362885 DMBXYKG Discontinued in Phase 1 NA [206]
JTT-651 DMGP42Q Discontinued in Phase 1 NA [207]
LY-315902 DMKMIQ6 Discontinued in Phase 1 NA [208]
NN-2501 DM95NDT Discontinued in Phase 1 NA [209]
NN9223 DM6R4LQ Discontinued in Phase 1 NA [210]
NN9928 DMPXSBE Discontinued in Phase 1 NA [211]
SB 418790 DMGHDTB Discontinued in Phase 1 NA [212]
SSR-162369 DMI3K2D Discontinued in Phase 1 Small molecular drug [213]
AC-187 DM5IDAQ Terminated Small molecular drug [219]
AD-5075 DM1SLJ9 Terminated Small molecular drug [220]
AKP-320 DMMTZXV Terminated NA [221]
AZM-134 DMIWC64 Terminated NA [222]
BMS-210285 DMMBTU6 Terminated Small molecular drug [223]
BVT-142 DMIYPLU Terminated NA [224]
Edaglitazone DMIC460 Terminated NA [225]
ERTIPROTAFIB DMJXEV7 Terminated Small molecular drug [226]
JTT-551 DM48HVI Terminated NA [227]
NNC-252504 DM0BYU2 Terminated NA [228]
PF-04620110 DMSNOH3 Terminated Small molecular drug [229]
PSN821 DMGEWUS Terminated NA [230]
PT-630 DMH3RPO Terminated NA [231]
SKF 38393 DMIMJ8Z Terminated Small molecular drug [232]
------------------------------------------------------------------------------------
⏷ Show the Full List of 53 Drug(s)
This Disease is Treated as An Indication in 10 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
LixiLan DM9USEM Application submitted NA [4]
Xultophy DMOUO3V Application submitted NA [4]
ASP8497 DMRPX4W Preclinical NA [214]
CL-314698 DM6HADZ Preclinical NA [9]
ER-319711-15 DMBINP0 Preclinical NA [215]
GCR-1087 DMFW0H9 Preclinical NA [9]
LY-2463665 DM7XPDB Preclinical NA [216]
Melanotetan II DMYK8MV Preclinical Small molecular drug [9]
SR3335 DM96IUW Preclinical Small molecular drug [217]
XL475 DMD8TNK Preclinical NA [218]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Drug(s)
This Disease is Treated as An Indication in 3 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
DB-900 DMGRUN1 Investigative NA [233]
Empagli ozin DMQLNZC Investigative NA [234]
NIS215 DMXMC6U Investigative NA [235]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7386).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4582).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4594).
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7638).
9 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6318).
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1133).
12 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
13 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
14 New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
15 Clinical pipeline report, company report or official report of Boehringer Ingelheim Pharmaceuticals.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7489).
17 ClinicalTrials.gov (NCT02234869) Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy. U.S. National Institutes of Health.
18 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
19 ClinicalTrials.gov (NCT01183013) 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks. U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT01664624) Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes. U.S. National Institutes of Health.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
22 Clinical pipeline report, company report or official report of Novo nordisk.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6316).
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286).
25 Tofogliflozin: first global approval. Drugs. 2014 Jun;74(8):939-44.
26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6310).
27 Clinical pipeline report, company report or official report of Taisho Pharmaceutical.
28 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
29 ClinicalTrials.gov (NCT02173457) Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients. U.S. National Institutes of Health.
30 ClinicalTrials.gov (NCT00690638) Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
31 ClinicalTrials.gov (NCT03496298) Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O). U.S. National Institutes of Health.
32 ClinicalTrials.gov (NCT02015780) Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis. U.S. National Institutes of Health.
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025107)
34 Clinical pipeline report, company report or official report of Gmax Biopharm.
35 Clinical pipeline report, company report or official report of Gmax Biopharm.
36 HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. Ann N Y Acad Sci. 2009 Sep;1173:781-90.
37 ClinicalTrials.gov (NCT01798238) Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT02501161) A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus.
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2675).
40 Clinical pipeline report, company report or official report of Diasome Pharmaceuticals.
41 ClinicalTrials.gov (NCT04460885) A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1). U.S. National Institutes of Health.
42 ClinicalTrials.gov (NCT02089126) Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes. U.S.National Institutes of Health.
43 ClinicalTrials.gov (NCT04605991) A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range). U.S. National Institutes of Health.
44 Clinical pipeline report, company report or official report of GlaxoSmithKline.
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8402).
46 Clinical pipeline report, company report or official report of Novo Nordisk A/S.
47 ClinicalTrials.gov (NCT01305109) A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E. U.S. National Institutes of Health.
48 Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
49 ClinicalTrials.gov (NCT00981669) Rotavirus Vaccine Produced by Butantan Institute. U.S. National Institutes of Health.
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6484).
51 Clinical pipeline report, company report or official report of Sanofi.
52 ClinicalTrials.gov (NCT02258867) Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis. U.S. National Institutes of Health.
53 ClinicalTrials.gov (NCT00387972) Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM). U.S. National Institutes of Health.
54 ClinicalTrials.gov (NCT00814294) Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT00940472) Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients. U.S. National Institutes of Health.
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008959)
57 ClinicalTrials.gov (NCT00698230) Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics. U.S. National Institutes of Health.
58 ClinicalTrials.gov (NCT01464437) AMG 151 Amgen Protocol Number 20100761. U.S. National Institutes of Health.
59 BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036000)
61 ClinicalTrials.gov (NCT02446028) A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog Mix 75/25 in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035050)
63 Clinical pipeline report, company report or official report of DiaMedica Inc.
64 ClinicalTrials.gov (NCT01551381) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects. U.S. National Institutes of Health.
65 FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8.
66 ClinicalTrials.gov (NCT01648153) Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM. U.S. National Institutes of Health.
67 ClinicalTrials.gov (NCT01218204) A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.U.S. National Institutes of Health.
68 Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
69 ClinicalTrials.gov (NCT01951235) A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
70 ClinicalTrials.gov (NCT00631007) A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator. U.S. National Institutes of Health.
71 Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006;45(8):789-801.
72 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
73 ClinicalTrials.gov (NCT01918865) Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes. U.S. National Institutes of Health.
74 ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
75 ClinicalTrials.gov (NCT01230749) A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
76 ClinicalTrials.gov (NCT02106585) Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects. U.S. National Institutes of Health.
77 ClinicalTrials.gov (NCT00997152) Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients. U.S. National Institutes of Health.
78 ClinicalTrials.gov (NCT01699737) Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
79 ClinicalTrials.gov (NCT00525330) A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone. U.S. National Institutes of Health.
80 ClinicalTrials.gov (NCT01824264) Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes. U.S. National Institutes of Health.
81 ClinicalTrials.gov (NCT02091362) A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
82 ClinicalTrials.gov (NCT00804986) A Study for Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
83 ClinicalTrials.gov (NCT01408095) A Study in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
84 ClinicalTrials.gov (NCT00290940) Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917. U.S. National Institutes of Health.
85 ClinicalTrials.gov (NCT00458016) Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
86 MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
87 ClinicalTrials.gov (NCT03596177) A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021640)
89 Clinical pipeline report, company report or official report of Mesoblast.
90 ClinicalTrials.gov (NCT01103414) Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients. U.S. National Institutes of Health.
91 ClinicalTrials.gov (NCT00846391) A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2). U.S. National Institutes of Health.
92 ClinicalTrials.gov (NCT02492763) A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004).
93 ClinicalTrials.gov (NCT01280695) A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients. U.S. National Institutes of Health.
94 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032961)
96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037506)
97 Clinical pipeline report, company report or official report of Medesis Pharma SA.
98 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028920)
100 ClinicalTrials.gov (NCT02060916) Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
101 Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.
102 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027641)
103 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7413).
104 ClinicalTrials.gov (NCT01517373) Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin. U.S. National Institutes of Health.
105 ClinicalTrials.gov (NCT01792635) A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
106 ClinicalTrials.gov (NCT02175121) Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
107 ClinicalTrials.gov (NCT02455011) Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
108 Clinical pipeline report, company report or official report of Bhv pharma.
109 ClinicalTrials.gov (NCT00823680) A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin. U.S. National Institutes of Health.
110 ClinicalTrials.gov (NCT00800176) A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus. U.S. National Institutes of Health.
111 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009313)
112 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031641)
113 ClinicalTrials.gov (NCT01035879) Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes.U.S. National Institutes of Health.
114 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031806)
115 ClinicalTrials.gov (NCT02332824) A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria. U.S. National Institutes of Health.
116 ClinicalTrials.gov (NCT00722917) Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
117 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035378)
118 ClinicalTrials.gov (NCT01665352) A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes. U.S. National Institutes of Health.
119 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021139)
120 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029155)
121 ClinicalTrials.gov (NCT00454233) A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects. U.S. National Institutes of Health.
122 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7866).
123 ClinicalTrials.gov (NCT00757926) Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants. U.S. National Institutes of Health.
124 Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
125 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4547).
126 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037723)
127 Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism. 2007 Mar;56(3):380-7.
128 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031821)
129 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035526)
130 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5727).
131 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028500)
132 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022196)
133 ClinicalTrials.gov (NCT01282970) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
134 ClinicalTrials.gov (NCT02211937) Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers. U.S. National Institutes of Health.
135 ClinicalTrials.gov (NCT01290575) Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
136 ClinicalTrials.gov (NCT01240980) Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B). U.S. National Institutes of Health.
137 Clinical pipeline report, company report or official report of Boston Therapeutics.
138 A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8.
139 ClinicalTrials.gov (NCT00882726) A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
140 ClinicalTrials.gov (NCT01301456) Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females. U.S. National Institutes of Health.
141 ClinicalTrials.gov (NCT00961025) A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects. U.S. National Institutes of Health.
142 ClinicalTrials.gov (NCT02004678) Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus. U.S. National Institutesof Health.
143 ClinicalTrials.gov (NCT01042106) Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults. U.S. National Institutes of Health.
144 ClinicalTrials.gov (NCT00854113) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers. U.S. National Institutes of Health.
145 PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
146 ClinicalTrials.gov (NCT01607385) A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.. U.S. National Institutes of Health.
147 Clinical pipeline report, company report or official report of Dia-B Tech.
148 ClinicalTrials.gov (NCT00519727) Safety Study of ISIS 325568 in Healthy Volunteers. U.S. National Institutes of Health.
149 ClinicalTrials.gov (NCT02120976) Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252. U.S. National Institutes of Health.
150 ClinicalTrials.gov (NCT01358981) A Study of LY2881835 in Healthy People and People With Diabetes. U.S. National Institutes of Health.
151 ClinicalTrials.gov (NCT01614782) A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002). U.S. National Institutes of Health.
152 ClinicalTrials.gov (NCT01640873) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1). U.S. National Institutes of Health.
153 ClinicalTrials.gov (NCT01971554) Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003). U.S. National Institutes of Health.
154 ClinicalTrials.gov (NCT01866462) Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin. U.S. National Institutes of Health.
155 ClinicalTrials.gov (NCT01405261) Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects. U.S. National Institutes of Health.
156 Clinical pipeline report, company report or official report of Medinox.
157 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024901)
158 ClinicalTrials.gov (NCT01472848) A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects. U.S. National Institutes of Health.
159 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036982)
160 ClinicalTrials.gov (NCT01874366) Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187. U.S. National Institutes of Health.
161 ClinicalTrials.gov (NCT01522807) A Study Of Three PF-05190457 Formulations In Healthy Volunteers. U.S. National Institutes of Health.
162 ClinicalTrials.gov (NCT01923389) Multiple Dose Study Of PF-05231023 In Obese Adult Subjects. U.S. National Institutes of Health.
163 ClinicalTrials.gov (NCT02211261) A Phase 1 Single Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
164 ClinicalTrials.gov (NCT02284425) Study of REGN1193 in Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
165 ClinicalTrials.gov (NCT01375907) Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults. U.S. National Institutes of Health.
166 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029833)
167 ClinicalTrials.gov (NCT01018628) A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers. U.S. National Institutes of Health.
168 ClinicalTrials.gov (NCT01340911) A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases. U.S. National Institutes of Health.
169 ClinicalTrials.gov (NCT02449330) Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study.
170 ClinicalTrials.gov (NCT00734201) Safety and Efficacy of Low Doses of V24343 in Obese Subjects. U.S. National Institutes of Health.
171 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030323)
172 Clinical pipeline report, company report or official report of Exelixis (2011).
173 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
174 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
175 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7405).
176 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 568).
177 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018893)
178 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025026)
179 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026051)
180 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022304)
181 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022135)
182 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013574)
183 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018957)
184 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030050)
185 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016521)
186 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024569)
187 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027843)
188 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022483)
189 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010490)
190 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034519)
191 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015327)
192 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012640)
193 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021020)
194 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018193)
195 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009164)
196 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031660)
197 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034341)
198 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016071)
199 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028284)
200 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020875)
201 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028644)
202 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025075)
203 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023882)
204 ClinicalTrials.gov (NCT00886366) Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients. U.S. National Institutes of Health.
205 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3491).
206 ClinicalTrials.gov (NCT01013766) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics. U.S. National Institutes of Health.
207 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026877)
208 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008960)
209 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018428)
210 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035332)
211 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039225)
212 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013384)
213 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022199)
214 ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol. 2008 Jul 1;76(1):98-107.
215 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl pepti... J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7.
216 Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012 Oct 1;20(19):5705-19.
217 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
218 Clinical pipeline report, company report or official report of Exelixis (2011).
219 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 689).
220 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2701).
221 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022081)
222 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008696)
223 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010623)
224 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30.
225 A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6.
226 Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol. 2005 Jan;67(1):69-77.
227 Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. J Diabetes Res. 2014;2014:680348.
228 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014586)
229 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7829).
230 Clinical pipeline report, company report or official report of Astellas Pharma (2011).
231 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022168)
232 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 935).
233 CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof.
234 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
235 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
236 ClinicalTrials.gov (NCT01734785) Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
237 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030467)
238 Clinical pipeline report, company report or official report of GlaxoSmithKline.
239 Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43.
240 ClinicalTrials.gov (NCT01518101) Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications. U.S. National Institutes of Health.
241 Clinical pipeline report, company report or official report of Sanofi.
242 ClinicalTrials.gov (NCT01508182) A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers. U.S. National Institutes of Health.